Sturis Jeppe, Gotfredsen Carsten F, Rømer John, Rolin Bidda, Ribel Ulla, Brand Christian L, Wilken Michael, Wassermann Karsten, Deacon Carolyn F, Carr Richard D, Knudsen Lotte Bjerre
Discovery, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Denmark.
Br J Pharmacol. 2003 Sep;140(1):123-32. doi: 10.1038/sj.bjp.0705397. Epub 2003 Jul 29.
(1) Liraglutide is a long-acting GLP-1 derivative, designed for once daily administration in type II diabetic patients. To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats. (2) When liraglutide was dosed s.c. at 150 microg kg-1 b.i.d. for 6 weeks in ZDF rats 6-8 weeks of age at study start, diabetes development was markedly attenuated. Blood glucose was approximately 12 mm lower compared to vehicle (P<0.0002), and plasma insulin was 2-3-fold higher during a normal 24-h feeding period (P<0.001). Judged by pair feeding, approximately 53% of the antihyperglycemic effect observed on 24-h glucose profiles was mediated by a reduction in food intake, which persisted throughout the study and averaged 16% (P<0.02). (3) Histological analyses revealed that beta-cell mass and proliferation were significantly lower in prediabetic animals still normoglycemic after 2 weeks treatment compared to vehicle-treated animals that had begun to develop diabetes. When the treatment period was 6 weeks, the liraglutide-treated animals were no longer completely normoglycemic and the beta-cell mass was significantly increased compared to overtly diabetic vehicle-treated animals, while beta-cell proliferation was unaffected. (4) In the experiments with 60% pancreatectomized rats, 8 days treatment with liraglutide resulted in a significantly lower glucose excursion in response to oral glucose compared to vehicle treatment. Again, part of the antihyperglycemic effect was due to reduced food intake. No effect of liraglutide on beta-cell mass was observed in these virtually normoglycemic animals. (5) In conclusion, treatment with liraglutide has marked antihyperglycemic effects in rodent models of beta-cell deficiencies, and the in vivo effect of liraglutide on beta-cell mass may in part depend on the metabolic state of the animals.
(1)利拉鲁肽是一种长效胰高血糖素样肽-1(GLP-1)衍生物,设计用于II型糖尿病患者的每日一次给药。为了研究利拉鲁肽对β细胞缺陷大鼠模型中血糖控制和β细胞量的影响,在雄性Zucker糖尿病肥胖(ZDF)大鼠和60%胰腺切除的大鼠中进行了研究。(2)在研究开始时6-8周龄的ZDF大鼠中,当利拉鲁肽以150微克/千克体重皮下注射,每日两次,持续6周时,糖尿病的发展明显减缓。与赋形剂相比,血糖降低约12毫摩尔(P<0.0002),在正常24小时喂食期血浆胰岛素高2-3倍(P<0.001)。通过配对喂食判断,在24小时血糖曲线观察到的约53%的降糖作用是由食物摄入量减少介导的,这种情况在整个研究过程中持续存在,平均为16%(P<0.02)。(3)组织学分析显示,与已开始患糖尿病的赋形剂处理动物相比,在治疗2周后仍血糖正常的糖尿病前期动物中,β细胞量和增殖明显较低。当治疗期为6周时,利拉鲁肽处理的动物不再完全血糖正常,与明显糖尿病的赋形剂处理动物相比,β细胞量显著增加,而β细胞增殖未受影响。(4)在60%胰腺切除大鼠的实验中,与赋形剂处理相比,利拉鲁肽治疗8天导致口服葡萄糖后血糖波动明显降低。同样,部分降糖作用归因于食物摄入量减少。在这些几乎血糖正常的动物中未观察到利拉鲁肽对β细胞量的影响。(5)总之,在β细胞缺陷的啮齿动物模型中,利拉鲁肽治疗具有显著的降糖作用,利拉鲁肽对β细胞量的体内作用可能部分取决于动物的代谢状态。